Sigma Pharmaceuticals Ltd
(ASX:SIP) has released its 2016 full year results, and its reported NPAT was $53.2 million (up 5.3% over its previous full year result).
On an underlying basis, excluding significant items, the company’s NPAT was up 13% to $66.9 million, on revenue of $4.4 billion (which rose 26.2%).
The wholesale and distribution pharmacy business also posted its underlying earnings before interest and tax jumped 12.4% to $100.2 million.
Sigma says these results were driven by opportunities it took to grow its non-PBS earnings. The company also says the Pharmaceutical Benefits Scheme remains a large and important part of its business, but is not a major contributor to earnings growth.
Sigma declared a fully franked final dividend of 3 cents per share, unchanged from last year.
This morning, Sigma shares are tracking 2.92% higher at $1.24.
